ENDRA Life Sciences (NDRA) Change in Receivables (2017 - 2018)
ENDRA Life Sciences (NDRA) posted quarterly Change in Receivables of -$12275.0 for Q4 2018, down 279.2% year-over-year from $6850.0 in Q4 2017, and down 2530.69% quarter-over-quarter from $505.0 in Q3 2018.
ENDRA Life Sciences (NDRA) Change in Receivables (2017 - 2018) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Change in Receivables for 2 consecutive years, with -$12275.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Change in Receivables fell 279.2% year-over-year to -$12275.0; the TTM figure through Sep 2019 stood at -$12275.0 (down 200.0% YoY), while the FY2018 annual figure was -$6850.0, down 200.0% from the prior year.
- Change in Receivables slipped to -$12275.0 in Q4 2018 per NDRA's latest filing, from $505.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $6850.0 in Q4 2017 and bottomed at -$12275.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | - |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | -71.00 Mn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 4.37 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | -12.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | - |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 26.04 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 26.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 25.09 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 59.20 Mn |
| 10 | ENDRA Life Sciences | 7.16 Mn | 1.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -12,275.00 |
| Dec 31, 2018 | -12,275.00 |
| Sep 30, 2018 | 505.00 |
| Sep 30, 2018 | 505.00 |
| Mar 31, 2018 | 4,920.00 |
| Mar 31, 2018 | 4,920.00 |
| Dec 31, 2017 | 6,850.00 |
| Dec 31, 2017 | 6,850.00 |